Compare VOYA & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VOYA | BIO |
|---|---|---|
| Founded | 1975 | 1952 |
| Country | United States | United States |
| Employees | N/A | 7450 |
| Industry | Life Insurance | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4B | 7.1B |
| IPO Year | N/A | N/A |
| Metric | VOYA | BIO |
|---|---|---|
| Price | $68.74 | $269.82 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 4 |
| Target Price | $85.90 | ★ $358.50 |
| AVG Volume (30 Days) | ★ 974.8K | 248.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.74% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.27 | $2.51 |
| Revenue Next Year | $4.98 | $3.17 |
| P/E Ratio | $12.00 | ★ $9.72 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $52.43 | $211.43 |
| 52 Week High | $79.99 | $343.12 |
| Indicator | VOYA | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 43.57 | 42.39 |
| Support Level | $66.17 | $266.71 |
| Resistance Level | $76.11 | $289.61 |
| Average True Range (ATR) | 2.41 | 7.55 |
| MACD | 0.11 | 0.36 |
| Stochastic Oscillator | 49.62 | 29.47 |
Voya Financial Inc is a financial services company, which, through its subsidiaries, provides various investment, insurance, and retirement solutions to individual and institutional clients in the United States. Its products and services include tax savings plans, individual retirement accounts, group life insurance plans, and employee benefits products, among others. The company tailors each of its products to the needs of its customer base. It operates its business through three principal lines: Wealth Solutions, Investment Management, and Health Solutions The Wealth segment generates roughly half of the company's revenue.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.